Published in Sleep on August 01, 2003
REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci (2010) 2.46
A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol (2008) 2.44
Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain (2009) 1.77
Phasic muscle activity in sleep and clinical features of Parkinson disease. Ann Neurol (2010) 1.64
Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med (2010) 1.62
Quantification of electromyographic activity during REM sleep in multiple muscles in REM sleep behavior disorder. Sleep (2008) 1.49
Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med (2013) 1.31
Neuroimaging insights into the pathophysiology of sleep disorders. Sleep (2008) 1.31
Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol (2013) 1.26
Elevated PEM (phasic electromyographic metric) rates identify rapid eye movement behavior disorder patients on nights without behavioral abnormalities. Sleep (2008) 1.22
REM sleep behavior disorder in the Korean elderly population: prevalence and clinical characteristics. Sleep (2013) 1.06
Circadian and sleep disorders in Parkinson's disease. Exp Neurol (2012) 1.03
Parasomnias: an updated review. Neurotherapeutics (2012) 0.98
Rapid eye movement sleep behavioral events: a new marker for neurodegeneration in early Parkinson disease? Sleep (2014) 0.97
Subclinical REM sleep behavior disorder and its clinical and research implications. Sleep (2008) 0.96
REM sleep behaviour disorder in older individuals: epidemiology, pathophysiology and management. Drugs Aging (2010) 0.93
Psychiatric issues in cognitive impairment. Mov Disord (2014) 0.91
Diagnostic tools for REM sleep behavior disorder. Sleep Med Rev (2011) 0.82
Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. J Neurol (2007) 0.82
Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson's disease. Brain (2016) 0.78
Loss of rapid eye movement sleep atonia in patients with REM sleep behavioral disorder, narcolepsy, and isolated loss of REM atonia. J Clin Sleep Med (2013) 0.77
Idiopathic REM sleep behavior disorder and Parkinson's disease--two sides of one coin? Sleep (2010) 0.77
Parasomnias. CMAJ (2014) 0.75
Recent progress of imaging agents for Parkinson's disease. Curr Neuropharmacol (2014) 0.75
Dopamine: A Modulator of Circadian Rhythms in the Central Nervous System. Front Cell Neurosci (2017) 0.75
A Review of Sleep and Its Disorders in Patients with Parkinson's Disease in Relation to Various Brain Structures. Front Aging Neurosci (2016) 0.75
Increased Motor Activity During REM Sleep Is Linked with Dopamine Function in Idiopathic REM Sleep Behavior Disorder and Parkinson Disease. J Clin Sleep Med (2016) 0.75
Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease. J Clin Sleep Med (2016) 0.75
Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis? NPJ Parkinsons Dis (2017) 0.75
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med (2003) 12.71
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science (2004) 5.94
Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med (2003) 4.95
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet (2007) 4.54
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
A humanized version of Foxp2 affects cortico-basal ganglia circuits in mice. Cell (2009) 3.63
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
RGS9 modulates dopamine signaling in the basal ganglia. Neuron (2003) 2.61
Sex and the risk of restless legs syndrome in the general population. Arch Intern Med (2004) 2.43
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int (2010) 2.27
Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology (2011) 2.17
Acute confusional States in the elderly--diagnosis and treatment. Dtsch Arztebl Int (2012) 2.16
EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging (2010) 2.09
Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord (2007) 1.96
Body weight in patients with Parkinson's disease. Mov Disord (2006) 1.89
Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev (2011) 1.88
Efficient generation of neural stem cell-like cells from adult human bone marrow stromal cells. J Cell Sci (2004) 1.79
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet (2008) 1.78
Psychosis pathways converge via D2high dopamine receptors. Synapse (2006) 1.78
Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res (2010) 1.76
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J Neurosci (2005) 1.74
Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet (2011) 1.70
Proposal: different types of alteration and loss of consciousness in epilepsy. Epilepsia (2014) 1.66
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord (2009) 1.62
Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain (2004) 1.54
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage (2004) 1.52
Focal epileptiform activity in the brain: detection with spike-related functional MR imaging--preliminary results. Radiology (2002) 1.50
Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord (2006) 1.49
Poor effect of guideline based treatment of restless legs syndrome in clinical practice. J Neurol Neurosurg Psychiatry (2010) 1.49
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging (2009) 1.49
Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. Sleep Med (2008) 1.48
FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging (2007) 1.47
Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging (2012) 1.47
Clinical symptomatology and treatment of restless legs syndrome and periodic limb movement disorder. Sleep Med Rev (2002) 1.46
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging (2009) 1.45
Adherence to antiparkinson medication in a multicenter European study. Mov Disord (2009) 1.34
Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med (2006) 1.33
Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med (2005) 1.32
Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol (2011) 1.32
The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet (2003) 1.30
The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PLoS One (2008) 1.29
Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging (2004) 1.28
Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med (2010) 1.27
Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet (2011) 1.27
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology (2013) 1.26
CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain (2006) 1.25
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol (2010) 1.24
Modern technology calls for a modern approach to classification of epileptic seizures and the epilepsies. Epilepsia (2012) 1.24
Iron metabolism and the risk of restless legs syndrome in an elderly general population--the MEMO-Study. J Neurol (2002) 1.23
The treatment of women with epilepsy. Dtsch Arztebl Int (2010) 1.22
Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter. Biochem Pharmacol (2002) 1.20
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett (2012) 1.19
European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging (2012) 1.19
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord (2010) 1.18
Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controls. Hum Brain Mapp (2011) 1.17
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol (2006) 1.17
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery (2005) 1.15
Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol (2008) 1.14
Comparative analysis of neuroectodermal differentiation capacity of human bone marrow stromal cells using various conversion protocols. J Neurosci Res (2006) 1.14
Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum. Orphanet J Rare Dis (2013) 1.13
Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. Acta Neuropathol (2014) 1.12
Pathophysiological concepts of restless legs syndrome. Mov Disord (2007) 1.12
Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine. J Clin Sleep Med (2011) 1.12
Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs (2004) 1.12
Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol (2006) 1.11
Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm (Vienna) (2009) 1.10
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord (2011) 1.10
Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord (2010) 1.10
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord (2006) 1.09
Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry (2009) 1.09
Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry (2009) 1.08
Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med (2008) 1.07
Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med (2007) 1.06
The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging (2010) 1.06
Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. J Neurol (2012) 1.05
Lack of hypoxia-inducible factor-1 alpha impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling. J Neurosci (2007) 1.05
α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm (Vienna) (2012) 1.04
Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry (2003) 1.04
Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord (2005) 1.03
Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol (2008) 1.03
Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? Eur J Nucl Med Mol Imaging (2007) 1.02
Mesodermal cell types induce neurogenesis from adult human hippocampal progenitor cells. J Neurochem (2006) 1.01
Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm (2005) 1.01
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer (2013) 1.00
Multipotent neural stem cells from the adult tegmentum with dopaminergic potential develop essential properties of functional neurons. Stem Cells (2005) 1.00
The localizing value of the abdominal aura and its evolution: a study in focal epilepsies. Neurology (2002) 1.00
Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett (2004) 0.99
Translation of stem cell therapy for neurological diseases. Transl Res (2010) 0.99
Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology (2007) 0.99
Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol (2002) 0.99
Heart rate increase in otherwise subclinical seizures is different in temporal versus extratemporal seizure onset: support for temporal lobe autonomic influence. Epileptic Disord (2005) 0.98